The Trade Desk increases share price range for IPO
Ventura-based digital marketing firm The Trade Desk increased the price range it expects to sell its shares for when the company holds its initial public offering. In documents filed with the Securities and Exchange Commission Sept. 22, The Trade Desk increased its pricing point to between $16 and $18 per share and expects to sell Read More →
Read More →QAD announces quarterly dividend
QAD announced a quarterly dividend of 7.2 cents per share for Class A common stock and 6 cents per share for Class B common stock on Sept. 15. QAD has declared the same dividend for 13 of the past 14 quarters. Headed by QAD President and Chairman Pamela Lopker and her husband and CEO Karl Read More →
Read More →Resonant plans to raise $9.2 million in public offering
Resonant, a late stage Goleta development company designing small smartphone technology, plans to raise $9.2 million in a public offering. Documents filed with the Securities and Exchange Commission Sept. 9 said the company plans to offer about 2.4 million shares for $4.25 per share. The company expects to complete the offering by Sept. 14. Resonant Read More →
Read More →Mission Wealth Management launches Social Values Portfolio
Santa Barbara-based financial advising firm Mission Wealth Management launched its new Social Values Portfolio, which aligns investments with an investor’s values. “The introduction of the Social Values Portfolio is in perfect alignment with Mission Wealth’s purpose as a business to serve both our clients and the community at large,” Mission Wealth CEO and founder Seth Streeter Read More →
Read More →
Greed drives skyrocketing cost of drugs in the U.S.
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Fiscal reform needed as pension time bomb ticks away
America’s summer of fiscal discontent is coming to a close on a downbeat note. The California legislature is preparing to wind up its session having stirred up a lot of controversy but done almost nothing to address the state’s ongoing pension crisis. The burgeoning shortfall now adds up to $139 billion in the CalPERS fund Read More →
Read More →FDA approves Amgen’s Blincyto
The U.S. Food and Drug Administration approved Amgen’s drug Blincyto for treating pediatric leukemia patients Sept. 1. In Dec. 2014, the FDA approved Blincyto to treat patients with precursor B-cell acute lymphoblastic leukemia, which is a rare form of the disease. On Sept. 1, the agency extended Blincyto’s approval to include pediatric patients with another Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
